UK eyes FDA if no EMA deal
This article is powered by OTC Bulletin & The Rose Sheet
Executive Summary
If the UK fails to secure full regulatory alignment with the European Union (EU) on medicines as part of negotiations over its ‘Brexit’ withdrawal from the EU, then the country may seek to align with the USFood and Drug Administration (FDA),according to a UK House of Commons health and social care committee report on the impact of Brexit on medicines.
You may also be interested in...
European Trade Groups To Cosmetics Firms: Be Prepared For ‘No Deal’ Brexit
The UK is converting the EU’s Cosmetics Regulation and REACH into UK law, holding out hope that mutual interests will yield an arrangement for “frictionless trade.” However, the Cosmetic, Toiletry and Perfumery Association notes “the political landscape is very uncertain.”
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.